IBDEI2BU ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,39465,0)
 ;;=E11.39^^153^1925^15
 ;;^UTILITY(U,$J,358.3,39465,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39465,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Ophthalmic Complications
 ;;^UTILITY(U,$J,358.3,39465,1,4,0)
 ;;=4^E11.39
 ;;^UTILITY(U,$J,358.3,39465,2)
 ;;=^5002643
 ;;^UTILITY(U,$J,358.3,39466,0)
 ;;=E11.36^^153^1925^14
 ;;^UTILITY(U,$J,358.3,39466,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39466,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Cataract
 ;;^UTILITY(U,$J,358.3,39466,1,4,0)
 ;;=4^E11.36
 ;;^UTILITY(U,$J,358.3,39466,2)
 ;;=^5002642
 ;;^UTILITY(U,$J,358.3,39467,0)
 ;;=E11.359^^153^1925^20
 ;;^UTILITY(U,$J,358.3,39467,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39467,1,3,0)
 ;;=3^DM Type 2 w/ Prolif Diab Retinopathy w/o Macular Edema
 ;;^UTILITY(U,$J,358.3,39467,1,4,0)
 ;;=4^E11.359
 ;;^UTILITY(U,$J,358.3,39467,2)
 ;;=^5002641
 ;;^UTILITY(U,$J,358.3,39468,0)
 ;;=E11.351^^153^1925^21
 ;;^UTILITY(U,$J,358.3,39468,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39468,1,3,0)
 ;;=3^DM Type 2 w/ Prolif Diab Retinopathy w/ Macular Edema
 ;;^UTILITY(U,$J,358.3,39468,1,4,0)
 ;;=4^E11.351
 ;;^UTILITY(U,$J,358.3,39468,2)
 ;;=^5002640
 ;;^UTILITY(U,$J,358.3,39469,0)
 ;;=E11.349^^153^1925^22
 ;;^UTILITY(U,$J,358.3,39469,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39469,1,3,0)
 ;;=3^DM Type 2 w/ Severe NonProlif Diab Retinopathy w/o Macular Edema
 ;;^UTILITY(U,$J,358.3,39469,1,4,0)
 ;;=4^E11.349
 ;;^UTILITY(U,$J,358.3,39469,2)
 ;;=^5002639
 ;;^UTILITY(U,$J,358.3,39470,0)
 ;;=E11.341^^153^1925^23
 ;;^UTILITY(U,$J,358.3,39470,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39470,1,3,0)
 ;;=3^DM Type 2 w/ Severe NonProlif Diab Retinopathy w/ Macular Edema
 ;;^UTILITY(U,$J,358.3,39470,1,4,0)
 ;;=4^E11.341
 ;;^UTILITY(U,$J,358.3,39470,2)
 ;;=^5002638
 ;;^UTILITY(U,$J,358.3,39471,0)
 ;;=E11.339^^153^1925^18
 ;;^UTILITY(U,$J,358.3,39471,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39471,1,3,0)
 ;;=3^DM Type 2 w/ Moderate NonProlif Diab Retinopathy w/o Macular Edema
 ;;^UTILITY(U,$J,358.3,39471,1,4,0)
 ;;=4^E11.339
 ;;^UTILITY(U,$J,358.3,39471,2)
 ;;=^5002637
 ;;^UTILITY(U,$J,358.3,39472,0)
 ;;=E11.331^^153^1925^19
 ;;^UTILITY(U,$J,358.3,39472,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39472,1,3,0)
 ;;=3^DM Type 2 w/ Moderate NonProlif Diab Retinopathy w/ Macular Edema
 ;;^UTILITY(U,$J,358.3,39472,1,4,0)
 ;;=4^E11.331
 ;;^UTILITY(U,$J,358.3,39472,2)
 ;;=^5002636
 ;;^UTILITY(U,$J,358.3,39473,0)
 ;;=E11.329^^153^1925^16
 ;;^UTILITY(U,$J,358.3,39473,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39473,1,3,0)
 ;;=3^DM Type 2 w/ Mild NonProlif Diab Retinopathy w/o Macular Edema
 ;;^UTILITY(U,$J,358.3,39473,1,4,0)
 ;;=4^E11.329
 ;;^UTILITY(U,$J,358.3,39473,2)
 ;;=^5002635
 ;;^UTILITY(U,$J,358.3,39474,0)
 ;;=E11.321^^153^1925^17
 ;;^UTILITY(U,$J,358.3,39474,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39474,1,3,0)
 ;;=3^DM Type 2 w/ Mild NonProlif Diab Retinopathy w/ Macular Edema
 ;;^UTILITY(U,$J,358.3,39474,1,4,0)
 ;;=4^E11.321
 ;;^UTILITY(U,$J,358.3,39474,2)
 ;;=^5002634
 ;;^UTILITY(U,$J,358.3,39475,0)
 ;;=E11.319^^153^1925^24
 ;;^UTILITY(U,$J,358.3,39475,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39475,1,3,0)
 ;;=3^DM Type 2 w/ Unspec Diab Retinopathy w/o Macular Edema
 ;;^UTILITY(U,$J,358.3,39475,1,4,0)
 ;;=4^E11.319
 ;;^UTILITY(U,$J,358.3,39475,2)
 ;;=^5002633
 ;;^UTILITY(U,$J,358.3,39476,0)
 ;;=E11.311^^153^1925^25
 ;;^UTILITY(U,$J,358.3,39476,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39476,1,3,0)
 ;;=3^DM Type 2 w/ Unspec Diab Retinopathy w/ Macular Edema
 ;;^UTILITY(U,$J,358.3,39476,1,4,0)
 ;;=4^E11.311
